News | Heart Failure | March 12, 2019

William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

Responsibilities will include supporting recently-launched 500-patient RELIEVE-HF pivotal study

William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

March 12, 2019 — V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief medical officer. Abraham makes this move to V-Wave after more than 16 years as director of the Division of Cardiovascular Medicine at the Ohio State University.

V-Wave is an early stage medtech company developing an implantable interatrial shunt device for treating advanced heart failure (HF) and pulmonary arterial hypertension (PAH).

Abraham has vast clinical trial experience with drugs and devices for heart failure. He has participated as a site principal investigator (PI) in more than 100 multicenter clinical drug and device trials, serving as national or international PI and/or on the executive or steering committees of more than 50 multicenter trials. He was the lead author on the landmark MIRACLE clinical trial for cardiac resynchronization therapy published in 2002, a lead PI for the CHAMPION implantable hemodynamic monitoring trial published in 2011, and one of the lead PIs for the recently published COAPT trial studying percutaneous mitral valve repair. He has participated in all regulatory phases of new device development from pre-clinical assessment through U.S. Food and Drug Administration (FDA) pre-market approval (PMA) submission and approval. He has authored more than 1,000 original research manuscripts and other papers, and has been published in high impact journals, including The New England Journal of Medicine, The Lancet and the Journal of the American Medical Association.

Watch the VIDEO: MitraClip to Treat Heart Failure - Results of the COAPT Trial, an interview with Abraham at TCT 2018

V-Wave CEO Neal Eigler, M.D., said that among Abraham’s duties will be supporting the recently launched 500-patient RELIEVE-HF pivotal study.

"I loved my leadership roles at Ohio State," noted Abraham. "Given the enormous potential impact of the V-Wave product, I am delighted that the next stage of my career will be focused on bringing the interatrial shunt to millions of patients worldwide. Advanced HF is a major public health problem in the U.S. and around the world, with more than 6 million Americans suffering from the condition. For decades, we have been managing severe heart failure, both preserved and reduced ejection fraction, using diuretics to modify total blood volume in order to control cardiac pressures. Interatrial shunting could supplement current therapies by providing a novel therapeutic approach that specifically regulates cardiac pressures and volumes. The V-Wave approach is physiologically validated and self-regulating, meaning that as left atrial pressure rises, the amount of shunting increases and this shift of volume from left to right atrium then lowers left atrial pressure, with the intent of improving patient symptoms and clinical outcomes."

Abraham earned his medical degree from Harvard Medical School and completed his residency in internal medicine and fellowships in cardiology and heart failure/cardiac transplantation at the University of Colorado Health Sciences Center. Previously at The Ohio State University, Abraham also served as deputy director of Ohio State's Dorothy M. Davis Heart and Lung Research Institute, associate dean for clinical research, and medical director of the Clinical Trials Management Office at the Medical Center. While stepping down from his division director and other leadership positions, Abraham will maintain his academic title as professor of internal medicine, physiology and cell biology, so he may continue to participate in patient care and scholarly activities at the university.

Watch the VIDEO: Technologies to Reduce Heart Failure Readmissions, an interview with Abraham at TCT 2016.

For more information: www.vwavemedical.com

Related Heart Failure Content

VIDEO: Vest May Help Reduce Heart Failure Readmissions

VIDEO: Therapies for Advanced Heart Failure

Related Content

Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.
Gallery | Cath Lab | October 31, 2019
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Overlay Init